Monday, July 24, 2017
Since we bought CYRX, the stock has gone up close to 200%. In the process, it has become by far the largest position in the Tailwinds Select Portfolio. Normally, this is a good thing as the winners get bigger and...
Shares of CYRX have been the best performer in the Tailwinds Select Portfolio. Since we initiated coverage on March 28, 2017, the shares have increased 133%, going from $2.09 to last night's closing price of $4.86. With the substantial share...
IRVINE, Calif., June 19, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM") quantifies the activity in the development and clinical trials of regenerative therapies in the United States, and acts as a means by which investors, the media...
Tailwinds' Take: CYRX's competitive strength will result in a number of partner relationships going forward as more trials move towards Phase III and commercialization.  IRVINE, Calif., June 7, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading cryogenic logistics...
This morning the FDA posted a note on their website that they would be having a panel review of Novartis' CAR-T therapy CTL019 (tisagenlecleucel-T) on July 12th. They will also be presenting their internal review documentation on July 10th for...
This video details the competitive strength and upcoming catalysts for CYRX.
I often refer to Silicon Valley as having a printing press for making money. It literally seems to grow on trees not only down in the valley, but in the whole Bay Area. However, despite the conception of every...
Tailwinds' Take: 27 new clients and 14 new trials demonstrates the strength of their competitive positioning in the growing biopharma space. The company is on the verge of a hockey stick inflection as more trials proceed through phases 1,...
As of this morning, at $2.09 per share, we have added Cryoport (CYRX) to the Tailwinds Select Portfolio. Cryoport is in the business of shipping medicines. Any biologic that needs to be cryogenically suspended until it is dosed into a...
Tailwinds' Take: This transaction will provide the needed cash to see CYRX through to cash-flow positive, an event that will happen in either the last Q of this year or first of next. Once this transaction closes, I believe...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address